Midazolam: Difference between revisions

No edit summary
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template))
Line 64: Line 64:
*Excretion: Renal
*Excretion: Renal
*Mechanism of Action: CNS depressant. Acts at GABA receptor to increase frequency of chloride channel opening, causing hyperpolarization and stabilization of neuronal membrane.
*Mechanism of Action: CNS depressant. Acts at GABA receptor to increase frequency of chloride channel opening, causing hyperpolarization and stabilization of neuronal membrane.
==Indications by Condition==
''The following table is automatically generated from disease/condition pages across WikEM.''
{{#ask:[[Has DrugName::Midazolam]]
|?Has Indication=Indication
|?Has Dose=Dose
|?Has Context=Context
|?Has Route=Route
|?Has Population=Population
|format=broadtable
|headers=plain
|link=subject
|sort=Has Indication
|limit=50
}}


==See Also==
==See Also==

Revision as of 16:42, 20 March 2026

See critical care quick reference for drug doses by weight.

General

Adult Dosing

  • Anxiolysis/sedation:
    • 1-2mg IV push
    • 0.07 to 0.08 mg/kg IM, usual dose 5 mg for 60 kg pt
  • Seizure:
    • 10mg IM/IV
  • ICU Sedation:
    • Load: 10-50mcg/kg IV infusion
    • Maintenance: 20-100 mcg/kg/hr infusion
    • Use with standardized sedation protocol for titration

Pediatric Dosing

See critical care quick reference for drug doses by weight.

  • Anxiolysis/sedation:
    • 6mo-5yr: 0.05-0.1 mg/kg IV push
    • 6-12yr: 0.025-0.05 mg/kg IV push
  • Intranasal
    • Seizure: 0.2 mg/kg IN divided between nostrils
    • Procedural sedation: 0.2-0.6 mg/kg IN divided between nostrils
    • Anxiolysis: 0.5 mg/kg IN (max dose 10 mg)

Special Populations

  • Pregnancy Rating: D
    • Maternal use shortly before delivery associated with floppy infant syndrome
  • Lactation: Distributed in breast milk, use with caution
  • Renal Dosing:
    • Adult: Decrease by 50% for severe renal failure
    • Pediatric
  • Hepatic Dosing:
    • Adult: Prolonged clearance in cirrhosis
    • Pediatric

Contraindications

  • Allergy to class/drug

Adverse Reactions

Serious

  • Apnea
  • Hypopnea
  • Hypotension
  • Delirium, when used for prolonged periods in ICU setting

Common

Pharmacology

  • Peak effect:
    • IM: Children: 15 to 30 minutes; Adults: 30 to 60 minutes
    • IV: 5 to 7 minutes
    • Intranasal: 10 minutes
  • Duration
    • IV: Single dose: <2 hours (dose-dependent),up to 6 hours with cirrhosis
    • IM: Up to 6 hours; Mean: 2 hours
    • Intranasal: Children: 18 to 41 minutes
  • Half-life: 1.8-6.4 hr
  • Metabolism: Metabolized in liver by CYP3A4 to active metabolite α1-hydroxymidazolam
  • Excretion: Renal
  • Mechanism of Action: CNS depressant. Acts at GABA receptor to increase frequency of chloride channel opening, causing hyperpolarization and stabilization of neuronal membrane.


Indications by Condition

The following table is automatically generated from disease/condition pages across WikEM.

 IndicationDoseContextRoutePopulation
Agitated or combative patient#Midazolam Benzodiazepine for agitation AdultAgitated or combative patient5 mg IMBenzodiazepine for agitationIMAdult
Excited delirium#Midazolam Benzodiazepine sedation AdultExcited delirium5 mgBenzodiazepine sedationIMAdult
Procedural sedation#Midazolam Procedural sedation (with fentanyl) AdultProcedural sedation1-2 mgProcedural sedation (with fentanyl)IVAdult
Rapid sequence intubation#Midazolam Induction AdultRapid sequence intubation0.2-0.3 mg/kgInductionIVAdult
Status epilepticus (peds)#Midazolam Prehospital first-line for pediatric status epilepticus PediatricStatus epilepticus (peds)0.2mg/kg IM/intranasal (max 10mg/dose)Prehospital first-line for pediatric status epilepticusIM/INPediatric

See Also

References

Micromedex